Published in Antimicrob Agents Chemother on October 01, 2000
Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother (2005) 1.83
Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol (2009) 1.06
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol (2008) 1.03
Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant (2008) 0.95
Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients. Clin Ophthalmol (2010) 0.92
Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics. J Control Release (2011) 0.91
Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes. Inflamm Bowel Dis (2013) 0.87
Management of cytomegalovirus infection and disease in liver transplant recipients. World J Hepatol (2014) 0.85
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother (2009) 0.84
Therapeutic applications of hydrogels in oral drug delivery. Expert Opin Drug Deliv (2014) 0.84
Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir. Liver Transpl (2012) 0.82
Current concepts on cytomegalovirus infection after liver transplantation. World J Hepatol (2010) 0.81
Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother (2009) 0.81
Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme. J Biol Chem (2009) 0.81
Increased adult hippocampal neurogenesis is not necessary for wheel running to abolish conditioned place preference for cocaine in mice. Eur J Neurosci (2014) 0.80
Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. BMC Infect Dis (2013) 0.80
Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis. J Res Med Sci (2014) 0.79
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. HPB (Oxford) (2010) 0.78
Cytomegalovirus Treatment. Curr Treat Options Infect Dis (2015) 0.78
Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. PLoS One (2015) 0.78
New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant (2013) 0.76
Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme. Antiviral Res (2009) 0.76
Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides. PLoS One (2013) 0.75
Detailed polymorphism study on cytomegalovirus DNA polymerase gene to reveal the most suitable genomic targets for quantitative Real-time PCR. Bosn J Basic Med Sci (2015) 0.75
Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation. Antimicrob Agents Chemother (2004) 0.75
Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management. J Clin Exp Hepatol (2017) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science (1994) 4.94
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med (1999) 2.33
Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev (1999) 2.05
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation (1999) 1.52
Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol (1999) 1.46
Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun (1998) 1.43
Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation (1998) 1.35
Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. J Gen Virol (1995) 1.26
Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet (1995) 1.24
Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation (1996) 1.22
Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis (1996) 1.19
Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos (1998) 1.04
Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs (1998) 1.01
Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet (1999) 1.01
A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. J Pharm Biomed Anal (1999) 0.89
Intraoperative hypothermia is an independent risk factor for early cytomegalovirus infection in liver transplant recipients. Transplantation (1999) 0.86
Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation (1998) 0.83
Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Pediatr Nephrol (1998) 0.81
Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. J Infect Dis (1999) 0.80
Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. Clin Transplant (1997) 0.80
An HPLC method for the determination of diastereomeric prodrug RS-79070-004 in human plasma. J Pharm Biomed Anal (1999) 0.80
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 18.17
Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant (2006) 8.03
Sulfonamide resistance gene for plant transformation. Plant Mol Biol (1990) 6.28
The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature (1989) 5.87
Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med (2000) 5.58
Classification of rhabdovirus proteins: a proposal. J Virol (1972) 5.54
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature (1987) 5.26
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med (1996) 3.63
Overlapping functions of components of a bacterial Sec-independent protein export pathway. EMBO J (1998) 3.59
The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol (1989) 3.53
The proteins of biologically active sub-units of vesicular stomatitis virus. J Gen Virol (1970) 3.44
Transport of proteins into chloroplasts. Partial purification of a chloroplast protease involved in the processing of important precursor polypeptides. Eur J Biochem (1984) 3.30
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15
Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int (2001) 3.07
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
Report of a National Conference on Donation after cardiac death. Am J Transplant (2006) 3.04
Detection of cytomegalovirus infections in specimens other than urine by the shell vial assay and conventional tube cell cultures. J Clin Microbiol (1987) 2.97
Survival benefit-based deceased-donor liver allocation. Am J Transplant (2009) 2.89
An essential component of a novel bacterial protein export system with homologues in plastids and mitochondria. J Biol Chem (1998) 2.86
The characterization of the promoter of the gene encoding the p50 subunit of NF-kappa B indicates that it participates in its own regulation. EMBO J (1992) 2.86
Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86
Dissection of vesicular stomatitis virus into the infective ribonucleoprotein and immunizing components. J Gen Virol (1970) 2.85
Export of active green fluorescent protein to the periplasm by the twin-arginine translocase (Tat) pathway in Escherichia coli. Mol Microbiol (2001) 2.71
Serological relationships between different strains of vesicular stomatis virus. J Gen Virol (1972) 2.68
The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med (1996) 2.67
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut (2005) 2.62
Kinetic tuning of myosin via a flexible loop adjacent to the nucleotide binding pocket. J Biol Chem (1998) 2.62
Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology (1984) 2.60
The ribonucleic acids of the infective and interfering components of vesicular stomatitis virus. J Gen Virol (1967) 2.57
Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest (1999) 2.53
Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature (1984) 2.52
Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol (1993) 2.50
The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant (2008) 2.48
3'-Terminal nucleotide sequences in the genome RNA of picornaviruses. Nature (1978) 2.40
Anomalous ABO phenotype in a child after an ABO-incompatible liver transplantation. N Engl J Med (1992) 2.36
Protein covalently linked to foot-and-mouth disease virus RNA. Nature (1977) 2.35
Location of the initiation site for protein synthesis on foot-and-mouth disease virus RNA by in vitro translation of defined fragments of the RNA. J Virol (1980) 2.34
Augmentation of permeability in the bronchial epithelium by the house dust mite allergen Der p1. Am J Respir Cell Mol Biol (1995) 2.30
Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer (1997) 2.30
A new type of signal peptide: central role of a twin-arginine motif in transfer signals for the delta pH-dependent thylakoidal protein translocase. EMBO J (1995) 2.29
Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med (1999) 2.27
Characterisation of a rotavirus.20b. Nature (1975) 2.21
Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut (2007) 2.20
The genetic analysis of bacterial spore germination. J Appl Bacteriol (1994) 2.19
Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol (2004) 2.18
Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS (1998) 2.15
TatB and TatC form a functional and structural unit of the twin-arginine translocase from Escherichia coli. J Biol Chem (2001) 2.11
TatD is a cytoplasmic protein with DNase activity. No requirement for TatD family proteins in sec-independent protein export. J Biol Chem (2000) 2.10
Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med (1984) 2.10
A physico-chemical sub-grouping of the mammalian picornaviruses. J Gen Virol (1973) 2.08
Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol (1996) 2.07
A re-appraisal of the biochemical map of foot-and-mouth disease virus RNA. J Gen Virol (1978) 2.06
Database comparison of the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the SRTR U.S. Transplant Registry. Am J Transplant (2010) 2.04
Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant (2008) 2.04
Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B. EMBO J (1994) 2.03
Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant (2010) 2.02
Transcription of the RelB gene is regulated by NF-kappaB. Oncogene (2001) 2.01
American Society of Transplant Surgeons transplant center outcomes requirements--a threat to innovation. Am J Transplant (2009) 2.00
Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature (1987) 2.00
Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet (2000) 1.99
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99
The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition. Medicine (Baltimore) (1965) 1.97
Transport of proteins into chloroplasts. The precursor of small subunit of ribulose bisphosphate carboxylase is processed to the mature size in two steps. Eur J Biochem (1984) 1.96
The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med (1984) 1.95
Sequence and location of the poly C tract in aphtho- and cardiovirus RNA. Nucleic Acids Res (1979) 1.95
Poly(C) in animal viral RNAs. Nature (1974) 1.95
Model for vesicular stomatitis virus. J Virol (1972) 1.92
Adherence: a necessity for successful HIV combination therapy. AIDS (1999) 1.91
Infective virus substructure from vesicular stomatitis virus. J Virol (1967) 1.89
The antigens of vesicular stomatitis virus. I. Separation and immunogenicity of three complement-fixing components. J Immunol (1966) 1.89
Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature (1990) 1.86
A proton gradient is required for the transport of two lumenal oxygen-evolving proteins across the thylakoid membrane. J Biol Chem (1991) 1.83
ALBINO3, an Arabidopsis nuclear gene essential for chloroplast differentiation, encodes a chloroplast protein that shows homology to proteins present in bacterial membranes and yeast mitochondria. Plant Cell (1997) 1.83
Fe-Chelate Reductase Activity of Plasma Membranes Isolated from Tomato (Lycopersicon esculentum Mill.) Roots : Comparison of Enzymes from Fe-Deficient and Fe-Sufficient Roots. Plant Physiol (1991) 1.83
Surface structure of vesicular stomatitis virus. J Gen Virol (1969) 1.82
Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry (2002) 1.81
Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage. Am J Gastroenterol (1997) 1.80
Further physicochemical characterization of Nodamura virus. Evidence that the divided genome occurs in a single component. J Gen Virol (1978) 1.78
p53 expression in colorectal tumors. Am J Pathol (1991) 1.77
Sclerosing encapsulating peritonitis after orthotopic liver transplantation. Am J Surg (2001) 1.74
A foot and mouth disease syndrome in pigs caused by an enterovirus. Nature (1968) 1.74
Molecular cloning of foot and mouth disease virus genome and nucleotide sequences in the structural protein genes. Nature (1981) 1.73
Clinical guidelines on the management of hepatitis C. Gut (2001) 1.72
Evaluation of the COBAS AMPLICOR CMV MONITOR test for detection of viral DNA in specimens taken from patients after liver transplantation. J Clin Microbiol (2000) 1.72
Casein kinase II phosphorylates I kappa B alpha at S-283, S-289, S-293, and T-291 and is required for its degradation. Mol Cell Biol (1996) 1.72
Antibody-complexed foot-and-mouth disease virus, but not poliovirus, can infect normally insusceptible cells via the Fc receptor. Virology (1993) 1.72
First-pass metabolism of cyclosporin by the gut. Lancet (1991) 1.71
A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis (1995) 1.71
More precise location of the polycytidylic acid tract in foot and mouth disease virus RNA. J Virol (1978) 1.69
Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol (1994) 1.69
Distribution of carbonate in thin sections of dental enamel. Caries Res (1968) 1.68
Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet (1987) 1.68
Recovery and utilization of deceased donor kidneys from small pediatric donors. Am J Transplant (2006) 1.68
A double blind placebo controlled crossover study of prostacyclin in man. Life Sci (1979) 1.67
Presence of a covalently linked protein on calicivirus RNA. J Gen Virol (1978) 1.66
CYP3A gene expression in human gut epithelium. Pharmacogenetics (1994) 1.66